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Abstract
Lipoprotein(a) (Lp(a)) is an internationally accepted independent atherogenic risk factor. Details about its synthesis, many
aspects of composition and clearance from the bloodstream are still unknown. LDL receptor (LDLR) (and probably
other receptors) play a role in the elimination of Lp(a) particles. Proprotein convertase subtilisin/kexin type 9 (PCSK9)
inhibitors increase the number of available LDLRs and in this way very effectively reduce the LDL cholesterol (LDL-C)
concentrations. As shown in controlled studies using PCSK9 inhibitors, Lp(a) levels are decreased by 20 to 30%, though
in some patients no effect was observed. So far, it has not been clarified whether this decrease is associated with an effect
on the incidence of cardiovascular events (CVEs). In two recently published well-performed secondary prevention studies
(FOURIER with evolocumab, ODYSSEY OUTCOMES with alirocumab) baseline Lp(a) levels were shown to have an
impact on CVEs independently of baseline LDL-C concentrations. The rather modest PCSK9 inhibitor-induced decrease
of Lp(a) was associated with a reduction of CVEs in both studies, even after adjusting (ODYSSEY OUTCOMES) for
demographic variables (age, sex, race, region), baseline Lp(a), baseline LDL-C, change in LDL-C, and clinical variables
(time from acute coronary syndrome, body mass index, diabetes, smoking history). The largest decrease of CVEs was seen
in patients with relatively low concentrations of both LDL-C and Lp(a) (FOURIER). These findings will probably have an
influence on the use of PCSK9 inhibitors in patients with high Lp(a) concentrations.
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Lipoprotein(a)—synthesis, composition,
metabolism, and clinical significance
Lipoprotein(a) (Lp(a)) consists of an LDL particle to which
an apolipoprotein(a) (apo(a)) is linked with a single disul-
fide bond. The binding between apolipoprotein (B) (apoB),
the major apolipoprotein of the LDL, and apo(a) takes place
either in the hepatic cells, in the space of Disse, or in the
vascular lumen [1]. The cholesterol content of the LDL in
Lp(a) varies between 30 and 45%. The Lp(a) concentra-
tion is genetically determined. Mutations in the Lp(a) gene
(LPA) and especially a variable number of LPA kringles IV
type 2 in the apo(a) have an effect. A low number of these
kringles is associated with higher Lp(a) levels.
This article is part of the special issue “Lp(a) – Update 2018”
 U. Julius
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The clearance of Lp(a) from the bloodstream is still not
fully understood. Hepatic (LDL receptor (LDLR), VLDL
receptor, scavenger receptor B1, LDL receptor–related pro-
tein 1, cluster of differentiation 36 receptor (CD36), plas-
minogen receptor) and nonhepatic receptors are probably
involved [1–4]. Renal mechanisms may also play a role.
It is assumed that LDLRs only play a significant role in
Lp(a) clearance when hepatic levels of the receptor are very
high and LDL-C levels are low, as is the case in propro-
tein convertase subtilisin/kexin type 9 (PCSK9) inhibitor
therapy. It is possible that apo(a) isoform length influences
clearance behavior of Lp(a) in human plasma following up-
regulation of LDLRs.
The physiological significance of Lp(a) particles may re-
late to their procoagulatory properties. Thus, wound healing
could be stimulated.
On the other hand, Lp(a) induces atherosclerotic lesions
and is supposed to promote aortic valve stenosis: a com-
bination of proatherosclerotic, proinflammatory and proco-
agulatory actions seems to be responsible [5]. Data suggest
that the atherogenicity of Lp(a) may be mediated in part by
proinflammatory oxidized phospholipids [6].
K
U. Julius et al.
Plasma PCSK9 is found in association with Lp(a) parti-
cles in humans with high Lp(a) levels and in mice carrying
human Lp(a) [7].
Studies using epidemiological data, Mendelian random-
ization and genome-wide associations have proven that el-
evated Lp(a) induce cardiovascular events (CVEs) like my-
ocardial infarction (MI), stroke, occlusions of carotids or of
leg arteries [5, 8].
New data obtained in the Danish population with re-
spect to the relationship between Lp(a) and mortality
have recently been published: In this study Lp(a) lev-
els >93mg/dl (199nmol/l; 96th–100th percentiles) versus
<10mg/dl (18nmol/l; 1st–50th percentiles) were associ-
ated with a hazard ratio (HR) of 1.50 (95% CI 1.28–1.76)
for cardiovascular mortality and of 1.20 (1.10–1.30) for
all-cause mortality [9]. High levels of Lp(a), induced by
low LPA kringle IV type 2 number of repeats rather than
through high cholesterol content, were associated with
increased mortality.
Lp(a) levels in the atherothrombotic range are gener-
ally accepted as >30 to 50mg/dl or >75 to 125nmol/l [1].
Such levels affect 20 to 30% of the global population, with
possibly higher incidence in patients with established car-
diovascular disease and calcific aortic valve disease.
PCSK9 inhibitors—mode of action
PCSK9 inhibitors are human monoclonal antibodies bind-
ing to the PCSK9 protein. This protein binds to LDLRs for
endocytosis and lysosome degradation in the liver, result-
ing in an increase in circulating LDL cholesterol (LDL-C)
level. LDLRs usually recycle after they transported LDL
particles into the cells. By inhibiting this LDLR destruc-
tion, the number of LDLRs at the cell surface markedly
increases—leading to an effective removal of circulating
LDL particles. Thus, reductions of LDL-C of more than
50% can be reached.
Evidently, the PCSK9 protein also exerts effects on other
receptors like VLDL receptor, LDL receptor-related pro-
tein 1 or the apolipoprotein E receptor [3].
It was shown that PCSK9 may increase the secretion of
apo(a) and of apoB—an inhibition of PCSK9 may counter-
act these effects [10]. Thus PCSK9 inhibitors reduce Lp(a)
levels by both increasing clearance and reducing its synthe-
sis.
Lp(a) kinetics were studied using intravenous D3-leucine
administration, mass spectrometry, and compartmental
modeling [11]. Evolocumab monotherapy was shown to
lower the plasma Lp(a) pool size by decreasing the produc-
tion of Lp(a) particles. In combination with atorvastatin,
evolocumab lowered the plasma Lp(a) pool size by accel-
erating the catabolism of Lp(a) particles.
Effects of PCSK9 inhibitors on Lp(a)
concentrations
Meta-analysis of randomized controlled trials with
PCSK9 inhibitors
A meta-analysis of studies using PCSK9 inhibitors (27
randomized controlled trials [RCTs] in 11,864 patients)
documented a mean reduction of Lp(a) levels by 21.90%
(95% CI 24.28, 19.51) [10]. Treatment modalities like
type of PCSK9 inhibitor, duration of therapy, application
in patients with or without familial hypercholesterolemia,
monotherapy or combination therapy, types of control
treatment (placebo, ezetimibe), baseline Lp(a) (below 50
or above 50mg/dl), and immunoassay did not have a sig-
nificant influence on this reduction. The lower the reached
LDL-C concentration was, the higher the reduction rate for
Lp(a). Attention should be paid to the fact that in the ma-
jority of the included studies mean Lp(a) ranged between 9
and 40mg/dl; however, in one investigation this value was
100 (but SD 162!) mg/dl.
Evolocumab in patients with very high Lp(a)
concentrations
In 65 patients with Lp(a) concentrations of about 200nmol/l
an injection therapy with 420mg evolocumab once in
4 weeks reduced Lp(a) after 16 weeks by 28.0 (56.5, 9.0)
nmol/l (median, IQR), equivalent to 13.9 (19.3, 8.5) percent
(mean, 95% CI) [12]. LDL-C was decreased by 2.2 (0.8)
mmol/l, corresponding to 60.7 (65.8, 55.5) percent (mean,
95% CI).
Interestingly, arterial wall inflammation (most diseased
segment target-to-background ratio (MDS TBR)) in the in-
dex vessel (left carotid, right carotid, or thoracic aorta) was
not changed by evolocumab. The explanation of the authors
for this lack of change is that Lp(a) levels remained high
despite the rather modest reduction induced by the PCSK9
inhibitor.
Eﬀect of PCSK9 inhibitors in patients undergoing
lipoprotein apheresis therapy
ODYSSEY ESCAPE Study
Alirocumab (150mg biweekly, 2:1 allocation to verum and
placebo, respectively) was given to patients (n =62) who
were treated with lipoprotein apheresis (LA) in order to
evaluate the possibility to replace LA therapy by the PCSK9
inhibitor [13]. Alirocumab reduced Lp(a) levels in those
patients with normal values (mean below 20mg/dl) after
6 weeks by 15% (placebo controlled) and after 18 weeks
by 2.7%. But in patients with high baseline Lp(a) concen-
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LDL-C 1 (mmol/l) LDL-C 2 (mmol/l) LDL-C reducon
m 3.66 1.74 -53.85%
sd 1.24 0.87 0.12
Max 8.24 4.16 -23.79%
Min 1.48 0.38 -81.42%
Lp(a) 1 (nmol/l) Lp(a) 2 (nmol/l) Lp(a) reducon
mean 199.00 156.35 -20.80%
SD 74.29 55.49 0.13
Max 376.00 247.00 -0.46%
Min 90.00 61.00 -44.35%
a b
Fig. 1 Individual percent reductions of LDL-C (a, n =41) and of Lp(a) (b, n =23) after 12 weeks of PCSK9 inhibitor application (usually biweekly)
in patients on LA therapy. LDL-C LDL cholesterol, Lp(a) Lipoprotein(a)
trations (mean above 90mg/dl) the corresponding changes
amounted to 13% and to +1.9% (placebo controlled).
Observations of the authors
At our center we initiated PCSK9 inhibitor therapy in
patients undergoing LA treatment when LDL-C levels re-
mained high despite maximally tolerated lipid-lowering
therapy (drugs, LA). Fig. 1 shows clear differences be-
tween patients with respect to lowering of LDL-C and
Lp(a) (12 weeks after start of the injection therapy), indi-
cating that reporting mean values is of limited significance
when describing the effectiveness of PCSK9 inhibitors.
Among the 41 patients who started PCSK9 inhibitor
therapy, only 23 showed elevated Lp(a) levels (higher than
120nmol/l before first LA session).
Outcome data in prospective controlled
PCSK9 inhibitor studies—association with
the effects of these drugs on Lp(a) levels
FOURIER Study
The randomized FOURIER (Further Cardiovascular Out-
comes Research with PCSK9 Inhibition in Patients with
Elevated Risk) Study tested the effect of evolocumab on
cardiovascular outcomes versus placebo in patients with
established atherosclerotic cardiovascular disease (median
follow-up 2.2 years) [14].
Lp(a) was measured in 25,096 patients [15]. The me-
dian (IQR) baseline Lp(a) concentration was 37 (13, 165)
nmol/l. In the placebo arm, patients with baseline Lp(a)
in the highest quartile had a higher risk of coronary heart
disease (CHD) death, MI or urgent revascularization (UR)
(adjusted HR Q4:Q1 1.22, 95% CI 1.01,1.48) independent
of LDL-C. At 48 weeks, evolocumab significantly reduced
Lp(a) by a median (IQR) of 26.9% (6.2, 46.7%)—equiv-
alent to 11nmol/l (1, 32) absolute change. It is important
to note that in more than 30% of the patients receiving
evolocumab no reduction of Lp(a) was seen!
The percent change in Lp(a) and LDL-C at 48 weeks in
evolocumab patients was moderately positively correlated.
Evolocumab reduced the risk of CHD death, MI or UR
by 23% (HR 0.77, 95% CI 0.67, 0.88) in patients with
a baseline Lp(a)> median, and by 7% (HR 0.93, 0.80, 1.08)
in those  median. Coupled with the higher baseline risk,
the absolute risk reductions and number-needed-to-treat for
3 years (NNT3y) were 2.49% and 40 vs. 0.95% and 105,
respectively.
When a clinical threshold of 120nmol/l (50mg/dl) was
applied, the absolute risk reductions and NNT3y were
2.41% and 41 for those above the threshold versus 1.41%
and 71 below the threshold.
In a weighted least square linear regression analysis that
examined the association between treatment effect on CHD
death, MI or UR and per unit decrease in Lp(a) adjusting
for differences in LDL-C, there was a significant relation-
ship with a 15% relative risk reduction (95% CI 2, 26%,
P= 0.0199) per 25nmol/l reduction in Lp(a).
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Table 1 CHD death, MI and UR beyond week 12 in dependence on
reached Lp(a) (median 29nmol/l) and LDL-C (median 65mg/dl) levels
LDL-C > median
(%)
LDL-C median
(%)
Lp(a)> median 8.52 7.09
Lp(a) median 7.33 5.86
LDL-C LDL cholesterol, Lp(a) Lipoprotein(a)
The authors observed a stepwise decrease in the risk of
CHD death, MI or UR for patients who achieved either
an Lp(a) or LDL-C value below the achieved median with
the lowest event rate observed for those who achieved lower
levels of both values. Compared with patients above the me-
dian achieved level for both lipid parameters, patients with
at least one level below the median had a 15% lower risk
of major coronary events (adjusted HR 0.85, 95% CI 0.75,
0.97, P= 0.01) and those with both levels below their re-
spective medians had a 29% lower risk of major coronary
events (adjusted HR 0.72, 95% CI 0.62, 0.83, P< 0.0001). It
was reported that consistent results were observed when pa-
tients were stratified by achieved values of LDL-C 70mg/dl
and Lp(a) 120nmol/l.
The incidence (3y KMrate, %) of the endpoint CHD
death, MI and UR beyond week 12 was different depend-
ing on whether the reached Lp(a) and LDL-C levels where
above or below the median (Table 1; [15]).
ODYSSEY OUTCOMES Trial
This is a multicenter, randomized, double-blind, placebo-
controlled trial involving 18,924 patients who had an acute
coronary syndrome 1 to 12 months earlier, had an LDL-C of
at least 1.8mmol/l (70mg/dl), a non-high-density lipopro-
tein cholesterol level of at least 2.6mmol/l (100mg/dl), or
an apoB level of at least 80mg/dl, and were receiving statin
therapy at a high-intensity dose or at the maximum tol-
erated dose [16]. Patients were randomly assigned to re-
ceive alirocumab subcutaneously or matching placebo ev-
ery 2 weeks.
Data on Lp(a) have been presented at the ISA congress in
Toronto (2018). The median level was 21.2mg/dl (IQR 6.7,
59.6). Major CVEs occurred in the baseline 4th quartile
more often than in the 1st quartile (HR unadjusted 1.37;
adjusted (for age, sex, race, geographic region, time since
event, BMI, smoking history, diabetes, baseline LDL-C)
1.28). A similar relationship was observed for non-fatal
MI. No relationship was found with stroke, cardiovascu-
lar death, or all-cause death. In the course of the study
alirocumab reduced Lp(a) levels in the mean by about
5mg/dl. After 4 months these reductions amounted to
9.8mg/dl (median; IQR 3.18, 16.2) in the 3rd quartile and
to 20.2mg/dl in the 4th quartile (median; IQR 8.0, 34.3),
more than in the 1st and 2nd quartiles.
Major CVEs were significantly reduced by alirocumab
in the baseline 3rd (HR 0.79 (95% CI 0.66, 0.95)) and
4th quartiles (HR 0.83 (95% CI 0.70, 0.98)). Similar HRs
were obtained after adjusting as detailed above. When the
time-weighted moving average Lp(a) change from baseline
was modeled with major CVEs or non-fatal MI significant
reductions of events (approximately by 16%) were seen,
even after adjusting for demographic variables (age, sex,
race, region), baseline Lp(a), baseline LDL-C, change in
LDL-C, and clinical variables (time from acute coronary
syndrome, body mass index, diabetes, smoking history).
Conclusions
An elevation of Lp(a) is currently no accepted indication
for PCSK9 inhibitors. Two reasons explain this situation:
(1) comparing with the effect on LDL-C concentrations,
the decrease of Lp(a) under PCSK9 inhibitors is rather
small—even absent in many patients, and (2) the associ-
ation of the described reduction of Lp(a) levels by 20–30%
with CVEs was unknown—new data on this topic appeared
only recently.
In two prospective controlled intervention studies with
both available PCSK9 inhibitors (evolocumab, alirocumab)
it could be shown that elevated baseline Lp(a) levels rep-
resent an atherogenic risk factor, independently of baseline
LDL-C concentrations.
It has to be remembered that Lp(a) levels were no in-
clusion criterion. Nonetheless, in the FOURIER Study ap-
proximately 33.1% of patients had a baseline concentration
higher than 120nmol/l (or approximately 50mg/dl) which
is believed to be the 80th percentile in a general patient
population [15].
The lowering of Lp(a) with the injection therapy reduced
the rate of CVEs—with modeling an influence of base-
line values or PCSK9 inhibitor-induced changes of LDL-
C or other factors could be excluded. The higher the base-
line Lp(a) concentrations were, the higher the reduction of
CVEs by the PCSK9 inhibitors was. These findings clearly
put this new class of lipid-lowering drugs into another per-
spective. Possibly high Lp(a) levels will be taken into con-
sideration when considering the use of these drugs in the
future. Of course, this indication would be valid only in
patients whose Lp(a) levels really demonstrate a decrease
on this injection therapy.
The missing effect of PCSK9 inhibitors on Lp(a) con-
centrations in up to 30% of patients is not yet fully under-
stood. Reasons, discussed in the literature, are the follow-
ing: (1) apo(a) with a low kringle IV type 2 number may less
actively bind to the LDLR, and (2) because furin-cleaved
PCSK9 is somewhat less effective on binding to LDLRs
compared with the intact PCSK9 form, it is possible that
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the balance between forms, as influenced by treatment with
a PCSK9 inhibitor, also contributes to the degree of Lp(a)
reduction on therapy [1].
The current therapeutic approach to improve the high-
risk situation in patients with high Lp(a) levels is to opti-
mize LDL-C below 1.8mmol/l (70mg/dl).
Given the proposed potentiation of the CVD risk between
LDL-C and Lp(a), Verbeek et al. hypothesized in 2018 that
the risk associated with elevated Lp(a) levels would largely
be attenuated at lower LDL-C levels [17]. They tested this
hypothesis in two large studies corresponding to a primary
prevention setting: the European Prospective Investigation
of Cancer (EPIC) Norfolk prospective population study
and the Copenhagen City Heart Study prospective popu-
lation study. At LDL-C levels, corrected for Lp(a)-derived
LDL-C, less than 2.5mmol/l (~100mg/dl), the risk associ-
ated with elevated Lp(a) decreases [17].
On the other hand, in statin studies where usually pa-
tients within secondary prevention were included, this sit-
uation is different. In an individual-patient data meta-anal-
ysis of statin-treated patients, patient-level data from seven
randomized, placebo-controlled, statin outcomes trials were
collated and harmonized to calculate HRs for CVEs, de-
fined as fatal or non-fatal coronary heart disease, stroke, or
revascularization procedures [18]. Elevated baseline and on-
statin Lp(a) showed an independent approximately linear
relation with cardiovascular disease risk, evident on treat-
ment with either statin or placebo.
Statins in contrast to PCSK9 inhibitors do not decrease
Lp(a) levels, but may even increase them. The parallel ef-
fect on both LDL-C and Lp(a) concentrations, as described
in PCSK9 inhibitor studies, appears to be a major progress.
It could be clearly shown that the optimization of both pa-
rameters reduces risk, but even the additional decrease of
LDL-C represents an advantage.
The measured LDL-C also contains cholesterol that is
transported with the Lp(a) particles [19]. This is a problem
in patients who on PCSK9 inhibitor therapy achieved rather
low LDL-C levels and who still show high Lp(a) values.
However, some patients still develop CVEs although
both target levels were rather low during the course of the
studies. The life-long burden with these lipoproteins could
be a possible explanation; both LDL-C and Lp(a) are ge-
netically determined.
In this context, the authors wish to emphasize that the
rate of new events in high-risk patients with elevated Lp(a)
concentrations on LA therapy is much lower [20, 21].
In the future, an antisense oligonucleotide against Lp(a)
will be tested in a phase III study which will probably start
in 2020. This study will clarify the effect of a of Lp(a)
reduction by more than 90% on CVEs [22].
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